MedicalJane

JUNE 29, 2018

percent of tetrahydrocannabinol (THC), the cannabinoid responsible for producing “high” psychoactive effects when consumed. Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree. The Next Move Is On The DEA. Epidiolex contains less than 0.1

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

JANUARY 11, 2019

Accordingly, the Drug Enforcement Administration (DEA) no longer has any claim to interfere with the interstate commerce of hemp products, so as long as the THC level is at or below 0.3%. While the DEA is now officially out of the hemp regulation business, the U.S. The FDA’s position on CBD is unsettled and unsupported by law.

Hemp 49

Hemp CBD Law Seed-To-Sale 49

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

SpeedWeed

DECEMBER 28, 2018

As first reported by Leafly, Altria has “over the past five years quietly patented dozens of devices that could be used to consume marijuana, a review of public documents at the US Patent and Trademark Office shows.” And then in December, Altria (formerly Phillip Morris) made a $1.8

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40

NORML

SEPTEMBER 20, 2019

We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. Essentially, the federal government has monopolized cannabis research, and ElSohly’s product, according to some scientists who’ve seen it, is unsuitable for clinical trials.

DEA 230

DEA Research and Development Clinical Trials Patients 230